Ligand Pharmaceuticals reported $948.6M in Assets for its fiscal quarter ending in June of 2025.


Assets Change Date
Amgen USD 87.9B 1.47B Jun/2025
Arrowhead Research USD 1.38B 192.89M Jun/2025
Baxter International USD 21.3B 4.48B Mar/2025
Bristol-Myers Squibb USD 94.68B 2.25B Jun/2025
Eli Lilly USD 100.92B 11.53B Jun/2025
Gilead Sciences USD 55.72B 713M Jun/2025
GlaxoSmithKline GBP 59.26B 1.45B Jun/2025
Glaxosmithkline GBP 59.26B 205M Jun/2025
Insmed USD 2.48B 677.12M Jun/2025
Ionis Pharmaceuticals USD 2.99B 172.18M Jun/2025
Ligand Pharmaceuticals USD 948.6M 43.17M Jun/2025
MacroGenics USD 245.42M 16.24M Jun/2025
Merck USD 117.52B 2.4B Jun/2025
Pacira USD 1.54B 49.41M Jun/2025
Pfizer USD 206.1B 1.93B Jun/2025
Veracyte USD 1.34B 28.69M Jun/2025